View More View Less
  • 1 Semmelweis Egyetem, Budapest, Mária u. 39., 1085
  • 2 Pécsi Tudományegyetem, Pécs
  • 3 Semmelweis Egyetem, Budapest
  • 4 Universitätsklinikum des Saarlandes, UKS, Homburg/Saar, Deutschland
Open access

Absztrakt:

Célunk a pigmentsejt-eredetű szemfelszíni elváltozások (conjunctivalis naevus, primer szerzett melanosis és conjunctivalis melanoma) összefoglaló ismertetése, különös hangsúlyt fektetve a klinikai megjelenésre, differenciáldiagnosztikára és kezelésre. A naevus a leggyakoribb benignus, pigmentsejt-eredetű conjunctivatumor. A primer szerzett (akvirált) melanosis közép- vagy időskorúakban jelenik meg, a conjunctivalis hám melanocytáinak proliferációja következtében. A conjunctivalis melanoma ritka daganat, a szemfelszíni laphám-neoplasia után a második leggyakoribb szemfelszíni malignus tumor, illetve a chorioidealis melanoma malignumot és a szemfelszíni laphám-neoplasiát követően a harmadik leggyakoribb ocularis malignoma. Rendkívül magas malignitási és áttétképzési potenciálja miatt fontos a korai felismerése és a megfelelő módon való kezelése. A gyakori recidívaképződés miatt kezelésében elengedhetetlen az intra- és posztoperatív adjuváns kezelési módok ismerete és alkalmazása, valamint a rendszeres kontrollvizsgálat. Orv Hetil. 2020; 161(15): 563–574.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Seregard S. Conjunctival melanoma. Surv Ophthalmol. 1998; 42: 321–350.

  • 2

    Jain P, Finger PT, Damato B, et al. Multicenter, international assessment of the eighth edition of the American Joint Committee on Cancer Cancer Staging Manual for conjunctival melanoma. JAMA Ophthalmol. 2019; 137: 905–911.

  • 3

    Tóth G, Sándor GL, Gyenes A, et al. Ocular surface squamous neoplasia. [Szemfelszíni laphám-neoplasia.] Orv Hetil. 2017; 158: 2011–2022. [Hungarian]

  • 4

    Kaštelan S, Gverović Antunica A, Beketić Orešković L, et al. Conjunctival melanoma – epidemiological trends and features. Pathol Oncol Res. 2018; 24: 787–796.

  • 5

    Folberg R, Jakobiec FA, Bernardino VB, et al. Benign conjunctival melanocytic lesions. Clinicopathologic features. Ophthalmology 1989; 96: 436–461.

  • 6

    Jakobiec FA. The ultrastructure of conjunctival melanocytic tumors. Trans Am Ophthalmol Soc. 1984; 82: 599–752.

  • 7

    Jakobiec FA, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology 1989; 96: 147–166.

  • 8

    Yu GP, Hu DN, McCormick S, et al. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol. 2003; 135: 800–806.

  • 9

    Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 2011; 118: 389–395.e2.

  • 10

    Tóth-Molnár E, Oláh J, Dobozy A, et al. Ocular pigmented findings in patients with dysplastic naevus syndrome. Melanoma Res. 2004; 14: 43–47.

  • 11

    Gilde K. Naevus pigmentosus and melanoma. [A naevus pigmentosus és a melanoma.] Magy Onkol. 2003; 47: 19–26. [Hungarian]

  • 12

    Tóth-Molnár E, Vizvári E, Skribek Á, et al. Giant conjunctival nevus in a 12-year-old child. Case Rep Ophthalmol Med. 2017; 2017: 8414352.

  • 13

    Liesegang TJ. Pigmented conjunctival and scleral lesions. Mayo Clin Proc. 1994; 69: 151–161.

  • 14

    Kurli M, Finger PT. Melanocytic conjunctival tumors. Ophthalmol Clin North Am. 2005; 18: 15–24.

  • 15

    Vizvári E, Skribek Á, Polgár N, et al. Conjunctival melanocytic naevus: diagnostic value of anterior segment optical coherence tomography and ultrasound biomicroscopy. PLoS ONE 2018; 13: e0192908.

  • 16

    Wachtel JG, Caplan CW, Makley TA Jr. Juvenile melanoma (mixed spindle cell and epithelioid cell nevus) of the conjunctiva. Surv Ophthalmol. 1967; 12: 12–16.

  • 17

    Alzahrani YA, Kumar S, Abdul Aziz H, et al. Primary acquired melanosis: clinical, histopathologic and optical coherence tomographic correlation. Ocul Oncol Pathol. 2016; 2: 123–127.

  • 18

    Shields CL, Shields JA. Conjunctival primary acquired melanosis and melanoma: tales, fairy tales, and facts. Ophthalmic Plast Reconstr Surg. 2009; 25: 167–172.

  • 19

    Lim LA, Madigan MC, Conway RM. Conjunctival melanoma: a review of conceptual and treatment advances. Clin Ophthalmol. 2013; 6: 521–531.

  • 20

    Orosz Z. Pitfalls in the diagnosis of malignant melanoma. [A melanoma malignum patológiai diagnózisának buktatói.] Magy Onkol. 2003; 47: 27–39. [Hungarian]

  • 21

    Berta-Antalics AI, Kruse FE, Holbach L. Pathology and prognostic factors of conjunctival melanoma. [Pathologie und Prognosefaktoren konjunktivaler Melanome.] Ophthalmologe 2015; 112: 892–898. [German]

  • 22

    Shields CL, Demirci H, Karatza E, et al. Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors. Ophthalmology 2004; 111: 1747–1754.

  • 23

    Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Indian J Ophthalmol. 2019; 67: 1930–1948.

  • 24

    Tóth-Molnár E. Primary melanocytic lesions of the conjunctiva. [A conjunctiva primer melanociter elváltozásai.] Szemészet 2015; 152: 102–111. [Hungarian]

  • 25

    Vora GK, Demirci H, Marr B, et al. Advances in the management of conjunctival melanoma. Surv Ophthalmol. 2017; 62: 26–42.

  • 26

    Glossmann JP, Skoetz N, Starbatty B, et al. Conjunctival melanoma: standard operating procedures in diagnosis, treatment and follow-up care. [Konjunktivales Melanom: Standardisiertes Vorgehen in Diagnostik, Therapie und Nachsorge.] Ophthalmologe 2018; 115: 489–498. [German]

  • 27

    Shildkrot Y, Wilson MW. Conjunctival melanoma: pitfalls and dilemmas in management. Curr Opin Ophthalmol. 2010; 21: 380–386.

  • 28

    Heindl LM, Koch KR, Schlaak M, et al. Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma. [Adjuvante Therapie und interdisziplinäre Nachsorge des Bindehautmelanoms.] Ophthalmologe 2015; 112: 907–911. [German]

  • 29

    Scholz SL, Hérault J, Stang A, et al. Proton radiotherapy in advanced malignant melanoma of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 2019; 257: 1309–1318.

  • 30

    Coupland SE, Campbell I, Damato B. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability. Ophthalmology 2008; 115: 1778–1785.

  • 31

    Pe’er J, Frucht-Pery J. The treatment of primary acquired melanosis (PAM) with atypia by topical mitomycin C. Am J Ophthalmol. 2005; 139: 229–234.

  • 32

    Módis L, Tóth E, Berta A. Surgical treatment of ocular surface diseases. [A szemfelszín betegségeinek sebészi kezelése.] Orv Hetil. 2009; 150: 1599–1606. [Hungarian]

  • 33

    Damato B, Coupland SE. Management of conjunctival melanoma. Expert Rev Anticancer Ther. 2009; 9: 1227–1239.

  • 34

    Westekemper H, Meller D, Darawsha R, et al. Operative therapy and irradiation of conjunctival melanoma. [Operative Therapie und Bestrahlung konjunktivaler Melanome.] Ophthalmologe 2015; 112: 899–906. [German]

  • 35

    Shields CL, Shields JA, Gündüz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000; 118: 1497–1507.

  • 36

    Tóth-Molnár E, Hammer H, Tiszlavicz L, et al. Conjunctival malignant melanoma in high grade lymphocytic lymphoma patient – case report. [Kifejezett malignitású non-Hodgkin T-sejtes lymphomás betegben kialakult melanoma malignum conjunctivae – esetleírás.] Szemészet 2000; 137: 209–211. [Hungarian]

  • 37

    Aziz HA, Gastman BR, Singh AD. Management of conjunctival melanoma: critical assessment of sentinel lymph node biopsy. Ocul Oncol Pathol. 2015; 1: 266–273.

  • 38

    Brouwer NJ, Marinkovic M, van Duinen SG, et al. Treatment of conjunctival melanoma in a Dutch referral centre. Br J Ophthalmol. 2018; 102: 1277–1282.

  • 39

    Missotten GS, Keijser S, De Keizer RJ, et al. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci. 2005; 46: 75–82.

  • 40

    Ditta LC, Shildkrot Y, Wilson MW. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ophthalmology 2011; 118: 1754–1759.

  • 41

    Herold TR, Hintschich C. Interferon α for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol. 2010; 248: 111–115.

  • 42

    Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol. 2008; 145: 124–129.

  • 43

    Kikuchi I, Kase S, Ishijima K, et al. Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection. Graefes Arch Clin Exp Ophthalmol. 2017; 255: 2271–2276.

  • 44

    Krause L, Ritter C, Wachtlin J, et al. Recurrence rate following adjuvant strontium-90 brachytherapy after excision of conjunctival melanoma. [Rezidivhäufigkeit nach Exzision von Bindehautmelanomen und adjuvanter Strontium-90-Kontaktbestrahlung.] Klin Monatsbl Augenheilkd. 2008; 225: 649–652. [German]

  • 45

    Karim R, Conway RM. Conservative resection and adjuvant plaque brachytherapy for early-stage conjunctival melanoma. Clin Exp Ophthalmol. 2011; 39: 293–298.

  • 46

    Wuestemeyer H, Sauerwein W, Meller D, et al. Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol. 2006; 244: 438–446.

  • 47

    Mor JM, Heindl LM. Systemic BRAF/MEK inhibitors as a potential treatment option in metastatic conjunctival melanoma. Ocul Oncol Pathol. 2017; 3: 133–141.

  • 48

    Sagiv O, Thakar SD, Kandl TJ, et al. Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma. JAMA Ophthalmol. 2018; 136: 1236–1241.

  • 49

    Pinto Torres S, André T, Gouveia E, et al. Systemic treatment of metastatic conjunctival melanoma. Case Rep Oncol Med. 2017; 2017: 4623964.

  • 50

    Dagi Glass LR, Lawrence DP, Jakobiec FA, et al. Conjunctival melanoma responsive to combined systemic BRAF/MEK inhibitors. Ophthalmic Plast Reconstr Surg. 2017; 33: e114–e116.